Business development news

Hudson Institute partner BiomeBank has secured a multimillion-dollar Federal Government grant that will turbocharge the development and production of microbiome-based therapeutics.…  Read more

A new treatment that controls the body’s response to influenza virus is shaping as the key to preventing dangerous lung inflammation and damage.…  Read more

A new blood test is now being developed to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery leading to better health outcomes, saving time, stress and money for patients and the healthcare system.…  Read more

Hudson Institute researcher, Dr Shayanti Mukherjee has been placed at Moderna Australia as one of the 2023 recipients of the MTPConnect REDI fellowship.…  Read more

Researchers are taking a new approach to a debilitating illness by looking for a microbiome-based cause of Inflammatory Bowel Disease (IBD).…  Read more

A new class of anti-inflammatory drug is opening a world of possibilities for treating everything from neurological diseases to cancers.…  Read more

The discovery of a new class of host-targeted therapy could give the medical profession a much-needed treatment option for serious flu infections.…  Read more

For the first time the mechanism that spreads antimicrobial resistance inside the human gut has been identified in the lab.…  Read more

A new anti-viral drug to target the cause of viral lung infections and the infection itself could be a game-changer in treating severe influenza.…  Read more

Many human diseases, including autoimmune diseases such as arthritis or inflammatory bowel disease, are characterised by too much inflammation.
There has been a gap in producing new generations of potent anti-inflammatory therapeutics for these anti-inflammatory conditions.…  Read more

Noxopharm plans to take Idronoxil (Veyonda®) to the next stage of testing following promising results in its first round of safety trials.…  Read more

RNA therapeutics comprise a rapidly expanding category of drugs that have the potential to revolutionise treatments for many diseases, including those currently deemed undruggable.…  Read more

Hudson Institute researchers Dr Daniel Croagh and Professor Brendan Jenkins have  received a share of the Australian Pancreatic Cancer Foundation’s (PanKind) 2020 Collaborative Research Grant to help accelerate…  Read more

Hudson Institute researchers have developed a new gene therapy strategy to treat beta thalassaemia, an inherited disorder where the body doesn’t make enough haemoglobin in red blood cells. These disorders lead to altered production of both haemoglobin and red blood cells, causing serious life-threatening complications soon after birth. …  Read more

Ten Hudson Institute PhD students have been selected for the second year running to participate in the high-level mentoring program, Industry Mentoring Network in STEM (IMNIS).…  Read more

Invion Limited ASX announcement on the initial proof-of-concept testing results on INV043, the latest Active Pharmaceutical Ingredient (“API”) using the PhotosoftTM technology.…  Read more

Invion, a life sciences company, announces it is progressing a new Active Pharmaceutical Ingredient (API) for anti-cancer treatment.…  Read more

Research into a chronic lung disease in premature babies is leading Hudson Institute researchers to develop new protocols on how to treat infants with cell-based therapies. …  Read more

A new Australian drug development company to target life-threatening inflammation has been formed as the result of a collaboration between Noxopharm Limited (ASX:NOX), Hudson Institute and Australian National University.…  Read more

Hudson Institute has attracted a substantial international venture capital investment to support translation of a promising new ovarian cancer therapy into clinical development.…  Read more

Biotech company Noxopharm is seeking approval from the US FDA for a clinical trial in COVID-19 patients of an end-stage prostate cancer drug, following a discovery by Hudson Institute researchers that it could act as an anti-inflammatory, to prevent a ‘cytokine storm’.…  Read more

An existing cancer drug could potentially modify a severe hyper-inflammatory ‘storm’ associated with some conditions, which may include the COVID-19 virus, according to Hudson Institute researchers.…  Read more

Hudson Institute has entered into a Research and Development Alliance Agreement with Invion Limited to provide key scientific assessment of Invion’s cancer treatment technology, Photosoft. The collaboration will initially focus on the treatment of ovarian cancer, with a view to expanding research and development projects into other forms of cancer.…  Read more

Hudson Institute’s finest medical researchers will continue to push the boundaries in their field thanks to continued generous support from Mr Peter Fielding and the Fielding Foundation. The Fielding Foundation Fellowship aims to help an outstanding early- to mid-career researcher to establish their own independent research.…  Read more

Two Hudson Institute researchers have been awarded 2018-19 Ferring Innovation Grants. Dr Fiona Cousins and Dr Tracey Edgell were named among eight international researchers, with this year’s program focused on reproductive medicine, women’s health and more.…  Read more

Hudson Institute of Medical Research and Monash University have announced a new research collaboration with the Swiss-based healthcare company Roche (F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.)…  Read more